Why the study?
Do direct oral anticoagulants (DOACs) provide comparable efficacy and improved safety compared to warfarin for long-term anticoagulation in patients with venous thromboembolism?
Do direct oral anticoagulants (DOACs) provide comparable efficacy and improved safety compared to warfarin for long-term anticoagulation in patients with venous thromboembolism?
Answers are grounded in this paper and cite their sources.
DOACs are preferred over warfarin for long-term VTE treatment due to comparable efficacy, lower bleeding risk, and lack of need for routine monitoring.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ryu et al. (2022) conducted a review in Venous thromboembolism. Direct oral anticoagulants vs. Warfarin was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: